This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Creatine riboside and *N*-acetylneuraminic acid (NANA) levels in urine as biomarkers of non–small cell lung cancer (NSCLC)	Patient studies suggest creatine riboside and NANA levels in urine could help diagnose or predict prognosis in NSCLC. In urine samples from 469 patients with NSCLC and 536 healthy individuals, creatine riboside and NANA were elevated in patient samples, with higher levels associated with worse prognosis. Results were validated in urine samples from an additional cohort of 158 recently diagnosed patients with NSCLC. Next steps include validating the biomarkers in prospective studies in additional patients with lung cancer. *SciBX* 7(20); doi:10.1038/scibx.2014.601 Published online May 22, 2014	Patent application filed; available for licensing	Mathe, E.A. *et al. Cancer Res.*; published online April 15, 2014; doi:10.1158/0008-5472.CAN-14-0109 **Contact:** Curtis C. Harris, National Institutes of Health, Bethesda, Md. e-mail: curtis_harris@nih.gov